Actively Recruiting
Randomized Study Evaluating Barrigel to Reduce Rectal Radiation Dose in Men Receiving Radiation Therapy After Prostatectomy for Recurrent Prostate Cancer
Led by Palette Life Sciences, Inc. · Updated on 2026-09-28
84
Participants Needed
13
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating Barrigel, a biodegradable gel designed to temporarily create space between the anterior rectal wall and the prostate or prostate bed during radiotherapy for prostate cancer. The goal is to reduce the radiation dose to the anterior rectum in men receiving external beam radiation therapy after prostatectomy for recurrent prostate cancer. This is a randomized, controlled, single-masked, multicenter study focused on safety and effectiveness. Participants will be randomly assigned to one of two groups. One group will receive an injection of Barrigel between the rectum and prostate bed guided by transrectal ultrasound to create space. The control group will undergo a sham procedure where a transrectal ultrasound probe is inserted without Barrigel injection. Barrigel is absorbable and maintains the space throughout the radiation therapy course. During the study, participants will receive moderately hypofractionated radiation therapy and be monitored for outcomes including reduction in rectal radiation exposure at 3 months. Researchers will assess side effects, bowel and urinary quality of life using specific questionnaires, and any grade 2 toxicities. Safety and treatment effects will be evaluated through imaging and clinical assessments. The study is expected to continue through December 2028.
CONDITIONS
Brief Title
Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
Research Team
J
Joseph Onokwai, MD, MPH, PhD
C
Cliff Kline
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here